

Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

Submission date 30/09/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 30/09/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 12/02/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Santbir Mehta

Contact details

University of Sheffield

Urology

Royal Hallamshire Hospital

Sheffield

United Kingdom

S26 4SY

+44 (0)788 956 9670/271 2154

sampimehta@aol.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0059132320

Study information

Scientific Title

Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

Study objectives

To identify any difference in relief of discomfort of prostate biopsy when using 1% or 2% lignocaine periprostatic nerve block

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Other

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Lignocaine

Primary outcome measure

Difference on visual analogue scale (VAS)

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2004

Completion date

30/04/2004

Eligibility

Key inclusion criteria

CaP (prostate cancer) patients

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

Not provided at time of registration

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/01/2004

Date of final enrolment

30/04/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
University of Sheffield
Sheffield
United Kingdom
S26 4SY

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Sheffield Teaching Hospitals NHS Foundation Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration